Skip to main content
BEAM logo

BEAM · Beam Therapeutics Inc.

Track BEAM — free
$20.90 -0.04 (-0.19%) At close · Nov 20
Market Cap
$2.16B
Shares
103.50M
Volume · Nov 20 3.89M Avg daily vol (3M) 2.05M

Price & Indicators

 

Key stats

Close
$20.90
Fri 20 Nov
Open
$20.60
Fri 20 Nov
Average volume, 30 days
2.2M
shares a session
Short interest
26.1M
25.2% of shares · 13.7 days to cover
Day range
$20.54$22.10
Open $20.60 Close $20.90
52-week closing range
$20.60$37.92
Close $20.90 44.9% under the high
Short volume, last session
52%
Last earnings
Oct 27, 2026
Latest filing
10-Q · Nov 3
Price history
Feb 2020 to Nov 2026

Up next

Jan 21, 2028 Est · unconfirmed · in 61 wks

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Risto-cel BLA planned as early as year-end 2026

Beam Therapeutics plans to submit a biologics license application (BLA) for risto-cel as early as year-end 2026, after completing dosing for all adult and adolescent patients in its BEACON trial.

Revenue $307K ▼ 96.8% Net loss $134.41M Diluted EPS -$1.28
Read from the MD&A section
2 source passages
Dosing in the BEACON trial is complete for all adult and adolescent patients. We expect to report updated data for the BEACON clinical trial by year-end 2026, and expect to submit a biologics license application, or BLA, for risto-cel as early as year-end 2026. Open the document at this passage
Nov 3
Current report 8-K
Cash runway expected into mid-2029

Beam Therapeutics expects to submit risto-cel's BLA as early as year-end 2026. It ended the third quarter with $1.0 billion in cash, cash equivalents and marketable securities, with runway expected into mid-2029.

Financial results
4 source passages
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises. Beam expects to report updated clinical data by year-end 2026 and submit a U.S. biologics license application (BLA) for risto-cel as early as year-end 2026. Cash, cash equivalents and marketable securities were $1.0 billion as of September 30, 2026, compared to $1.2 billion as of December 31, 2025. Beam expects that its cash, cash equivalents and marketable securities as of September 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, assuming satisfaction of the conditions applicable to those additional borrowings. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$146.64M
Trailing 12 months
Net income (TTM)
−$108.35M
Trailing 12 months
Revenue growth YoY
-96.8%
Year over year
Operating margin
-267.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-18.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$943.51M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
+1.5%
Trailing year
Short interest
25.2%
Latest settlement · 13.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −15%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −28%
trailing
YTD return −25%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $25 › 200d $28 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +38 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
25.20% of shares out · ▼ -0.6% MoM · 13.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
268 holders — mid 3-yr range
Squeeze score 69
elevated · 0–100
Fundamentals
Strong
Revenue growth +33%
Y/Y
EPS growth +82%
Y/Y
Free cash flow $-360.0M
Balance sheet $294.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 73%
annualized · 1-yr
Max drawdown −46%
past year
ATR 8.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $25 › 200d $28 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +38 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
25.20% of shares out · ▼ -0.6% MoM · 13.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
268 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $21 Now $21 · 2% Range high $38
vs 200-day avg -25% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BEAM
Beam Therapeutics Inc.
this stock
$2.16B -24.6% +33.3% — 25.2%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
268
% held
108.5%
Net QoQ
+2.9M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
268
View
Short & Settlement
Short Interest Falling
Shares short
26.1M
Days to cover
13.7d
Change
-160.7K sh
View
Short Volume
Short vol %
52%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
340
Value
$9.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
43.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$139.7M
Net income (FY)
$-80.0M
EPS diluted
$-0.81
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
20

Beam's CEO said top-line sickle cell data were positive, keeping a BLA filing on track for as early as December.

View
Proposed Sales
Value
$599.6K
Shares
25.0K
Filed
Oct 16, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Beam Therapeutics Announces Posit…
Published
Nov 10, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
BEAM -8.5% -13.1% -27.8% -23.3% -24.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +0.1% -3.9% -18.7% -14.5% -25.8%
Key facts CIK 1745999 CUSIP 07373V105 13F (30d) 270 filings 247 filers Visit website Investor relations